HomeCompareSCRSF vs ABBV

SCRSF vs ABBV: Dividend Comparison 2026

SCRSF yields 100000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCRSF wins by $4.832206901976048e+26M in total portfolio value
10 years
SCRSF
SCRSF
● Live price
100000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.832206901976048e+26M
Annual income
$482,271,988,201,431,700,000,000,000,000,000.00
Full SCRSF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SCRSF vs ABBV

📍 SCRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCRSFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCRSF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCRSF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCRSF
Annual income on $10K today (after 15% tax)
$8,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$409,931,189,971,216,900,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SCRSF beats the other by $409,931,189,971,216,900,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCRSF + ABBV for your $10,000?

SCRSF: 50%ABBV: 50%
100% ABBV50/50100% SCRSF
Portfolio after 10yr
$2.416103450988024e+26M
Annual income
$241,135,994,100,715,840,000,000,000,000,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SCRSF
No analyst data
Altman Z
-28.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCRSF buys
0
ABBV buys
0
No recent congressional trades found for SCRSF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCRSFABBV
Forward yield100000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.832206901976048e+26M$102.3K
Annual income after 10y$482,271,988,201,431,700,000,000,000,000,000.00$24,771.77
Total dividends collected$4.8315851896727036e+26M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SCRSF vs ABBV ($10,000, DRIP)

YearSCRSF PortfolioSCRSF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,010,700$10,000,000.00$11,550$430.00+$10.00MSCRSF
2$9,366,505,842$9,355,794,392.52$13,472$627.96+$9366.49MSCRSF
3$8,191,091,111,834$8,181,068,950,583.78$15,906$926.08+$8191091.10MSCRSF
4$6,695,134,751,499,451$6,686,370,284,009,789.00$19,071$1,382.55+$6695134751.48MSCRSF
5$5,114,850,040,116,031,000$5,107,686,245,931,928,000.00$23,302$2,095.81+$5114850040116.01MSCRSF
6$3,652,290,278,277,141,000,000$3,646,817,388,734,216,400,000.00$29,150$3,237.93+$3652290278277141.00MSCRSF
7$2,437,583,176,648,375,000,000,000$2,433,675,226,050,619,000,000,000.00$37,536$5,121.41+$2437583176648375296.00MSCRSF
8$1,520,612,508,079,010,700,000,000,000$1,518,004,294,079,997,000,000,000,000.00$50,079$8,338.38+$1.5206125080790106e+21MSCRSF
9$886,637,379,601,106,600,000,000,000,000$885,010,324,217,461,900,000,000,000,000.00$69,753$14,065.80+$8.866373796011065e+23MSCRSF
10$483,220,690,197,604,800,000,000,000,000,000$482,271,988,201,431,700,000,000,000,000,000.00$102,337$24,771.77+$4.832206901976048e+26MSCRSF

SCRSF vs ABBV: Complete Analysis 2026

SCRSFStock

Justera Health Ltd., together with its subsidiaries, operates as a health and wellness management company in Canada. The company operates GoStop, a COVID-19 digital testing platform; and provides COVID-19 screening services to businesses and government organizations. It also operates Juillet Wellness Spas, a full-service wellness centre, that provides skincare, medical grade facials, physiotherapy, body massages, registered massage therapy, acupuncture, and laser hair removal services; and distributes TonyMoly skin care products. In addition, the company offers health supplements, protein products, beauty, and pet care solutions; and provides concierge medical services, including urgent concierge medical care, IV vitamin therapy, medical advisory, and preventive screenings to determine the presence or absence of disease. Justera Health Ltd. was founded in 2020 and is headquartered in Toronto, Canada.

Full SCRSF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SCRSF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCRSF vs SCHDSCRSF vs JEPISCRSF vs OSCRSF vs KOSCRSF vs MAINSCRSF vs JNJSCRSF vs MRKSCRSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.